Naproxen's primary patents have long expired, allowing for the widespread availability of generic versions. This means that the manufacturing and sale of naproxen are no longer restricted to the original patent holder.
When Did Naproxen Patents Originally Expire?
Naproxen was first patented by Syntex Corporation in the 1960s. The key compound patents for naproxen expired in the 1980s [1]. This patent expiration opened the door for other pharmaceutical companies to develop and market their own versions of the drug.
What is the Current Status of Naproxen Exclusivity?
Because the foundational patents for naproxen have expired, there is no longer market exclusivity for the drug itself. This has led to a competitive generic market for naproxen [1]. DrugPatentWatch.com tracks patent and exclusivity information for pharmaceuticals, and for established drugs like naproxen, the primary patent protections have long lapsed [2].
Why is Generic Naproxen Widely Available?
The expiration of naproxen's patents in the 1980s removed the legal barriers to entry for other manufacturers. This allowed generic drug companies to produce and sell naproxen, leading to increased competition and typically lower prices for consumers compared to branded versions [1].
How Does Naproxen's Patent Situation Differ from Newer Drugs?
Newer medications often have more recent patent filings and may also benefit from regulatory exclusivities granted by agencies like the FDA. These protections can extend market exclusivity for a significant period, even after primary patents expire. Naproxen, being an older drug, has gone through its entire patent and exclusivity lifecycle [2].